The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung cancer. The trial, which is the first to open through the newly formed National Cancer Institute (NCI) Clinical Trials Innovation Unit (CTIU), aims to evaluate the role of immunotherapy before and after surgery in patients with non-small cell lung cancer.

A quality improvement program designed to increase earlier uptake of the human papillomavirus (HPV) vaccine raised vaccination rates significantly, according to a study by Nemours Children’s Health researchers.

A groundbreaking new database could lead to vast improvements in precision oncology by documenting sex-based differences in cancer treatment efficacy, biomarkers, risk factors, and microbial influences across 71 cancer types. The database — created by researchers at the Yale School of Public Health (YSPH), Yale School of Medicine (YSM), and international collaborators — addresses a significant gap in current research and demonstrates how biological sex can comprehensively impact cancer onset, progression, and therapeutic outcomes, the researchers said.

The project, which the researchers call OncoSexome, was created in response to the tendency of scientists and clinicians to overlook sex differences in clinical trials.